Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Universe Pharmaceuticals Inc (UPC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: UPC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -44.5% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.06M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.51 | 52 Weeks Range 2.51 - 2592.00 | Updated Date 06/29/2025 |
52 Weeks Range 2.51 - 2592.00 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -639.5 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -37.9% | Operating Margin (TTM) -61.93% |
Management Effectiveness
Return on Assets (TTM) -9.14% | Return on Equity (TTM) -23.76% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -19447324 | Price to Sales(TTM) 0.09 |
Enterprise Value -19447324 | Price to Sales(TTM) 0.09 | ||
Enterprise Value to Revenue 0.02 | Enterprise Value to EBITDA 0.31 | Shares Outstanding 563338 | Shares Floating 42879 |
Shares Outstanding 563338 | Shares Floating 42879 | ||
Percent Insiders 0.61 | Percent Institutions 0.05 |
Upturn AI SWOT
Universe Pharmaceuticals Inc
Company Overview
History and Background
Universe Pharmaceuticals Inc., founded in 2004, is a specialty pharmaceutical company focusing on traditional Chinese medicine (TCM) products and modern medicine. They initially focused on distribution before transitioning to manufacturing and product development.
Core Business Areas
- TCM Products: Development, manufacturing, and marketing of TCM products for various ailments.
- Pharmaceutical Products: Production and distribution of chemical and biological pharmaceuticals.
- Nutraceuticals: Manufacturing and sale of dietary supplements and health foods.
Leadership and Structure
The leadership team includes a CEO, CFO, and heads of various departments like R&D, manufacturing, and marketing. The organizational structure is typical of a mid-sized pharmaceutical company, with functional departments reporting to executive management.
Top Products and Market Share
Key Offerings
- Gan Mao Ling Granules: A popular TCM cold remedy. Market share estimated at 15% in its category in China. Competitors include Baiyunshan Pharmaceutical.
- Xue Zhi Kang Capsules: A cholesterol-lowering TCM product. Market share estimated to be 10% in China. Competitors include CR Pharmaceuticals.
- Yi Gan Ning Tablets: A liver health supplement. No definitive market share data is available. Competitors include Tasly Pharmaceuticals
Market Dynamics
Industry Overview
The pharmaceutical industry is experiencing growth driven by an aging population, increasing healthcare expenditure, and technological advancements. TCM is growing in popularity.
Positioning
Universe Pharmaceuticals occupies a niche position focusing on TCM while also producing modern medicine. Their competitive advantage lies in their expertise in TCM and their established distribution network within China.
Total Addressable Market (TAM)
The global pharmaceutical market is estimated to be worth over $1.4 trillion USD. The Chinese TCM market is estimated to be in the tens of billions of USD. Universe Pharma is positioned to capture a portion of the Chinese TCM and pharmaceutical market.
Upturn SWOT Analysis
Strengths
- Strong TCM product portfolio
- Established distribution network in China
- Experience in manufacturing both TCM and pharmaceutical products
- Brand recognition within certain regional markets
Weaknesses
- Limited international presence
- Reliance on a few key products
- Potential regulatory risks associated with TCM
- Competition from larger pharmaceutical companies
Opportunities
- Expanding into new geographic markets (e.g., Southeast Asia)
- Developing new TCM-based products
- Acquiring smaller pharmaceutical companies
- Entering into partnerships with international players
Threats
- Increased competition from generic drugs
- Changes in government regulations related to healthcare
- Price pressures from healthcare providers
- Fluctuations in raw material costs
Competitors and Market Share
Key Competitors
- CR Pharmaceuticals (1099.HK)
- Baiyunshan Pharmaceutical (600332.SS)
- Tasly Pharmaceutical (600535.SS)
Competitive Landscape
Universe Pharmaceuticals competes with larger, more established pharmaceutical companies. Their advantage lies in their TCM expertise, but they face challenges in terms of scale and resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is not readily available.
Future Projections: Future growth projections are unavailable due to limited data.
Recent Initiatives: Information on recent strategic initiatives is not easily accessible.
Summary
Universe Pharmaceuticals is a specialty pharmaceutical company with a focus on TCM products. It has an established presence in China and competes with larger players in the pharmaceutical market. While it has strengths in TCM and distribution, it faces challenges related to competition and international expansion. They would benefit from a strategic push into a specific market segment.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company information (where available)
- Industry reports and market analysis
- Analyst estimates (where available)
Disclaimers:
The information provided is based on available data and is subject to change. Market share estimates are approximations. The AI-based rating is for informational purposes only and should not be considered investment advice. Data is limited, thus rating is speculative.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Universe Pharmaceuticals Inc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-03-23 | CEO & Chairman Mr. Gang Lai | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 225 | |
Full time employees 225 | |||
Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacturing, marketing, distribution, and sells of traditional Chinese medicine derivative products in China. The company offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. It also provides guben yanling, shenrong weisheng, and quanlu pill; yangxue danggui and qiangli pipa syrup; wuzi yanzong oral, fengtong medicinal, shenrong medicinal, qishe medicinal, fengshitong medicinal, and shiquan dabu medicinal liquor; paracetamol granule for children; and isatis root granule. In addition, the company distributes and sells third-party products, including biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements. It primarily serves pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was founded in 1998 and is headquartered in Ji'An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.